

Highlights of This Issue 3297

HIGHLIGHTS

Special Report

- 3299 | **AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development**
Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

CCR Translations

- 3319 | **ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?**
Adam M. Lee and Robert B. Diasio
See article p. 3378

CCR New Strategies

- 3322 | **New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK**
Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda

MOLECULAR PATHWAYS

- 3329 | **Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response**
Christine A. Pratilas and David B. Solit
- 3335 | **The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment**
Ivor Caro and Jennifer A. Low

HUMAN CANCER BIOLOGY

- 3340 | **BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood**
Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich G. Weier, Krzysztof P. Bielawski, and Burkhard Brandt

- 3349 | **Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer**
Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

- 3356 | **Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome**
Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletic, Markus Ringnér, Johan R. Lillehaug, Åke Borg, and Per Eystein Lønning

- 3368 | **A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas**
Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoriadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Safa Al-Sarraj, Darren Hargrave, and Chris Jones

CANCER THERAPY: PRECLINICAL

- 3378 | **Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer**
Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, and Patrick G. Johnston
See commentary p. 3319

- 3390 | **The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells *In vitro* and *In vivo***
Julian Paesler, Iris Gehrke, Rajesh Kumar Gandhirajan, Alexandra Filipovich, Magdalena Hertweck, Felix Erdfelder, Sabrina Uhrmacher, Simon Jonas Poll-Wolbeck, Michael Hallek, and Karl-Anton Kreuzer

- 3399 | **Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy**
Darya Alizadeh, Laying Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie

3409 **Role of Type-1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans**
Mitsugu Fujita, Michael E. Scheurer, Stacy A. Decker, Heather A. McDonald, Gary Kohanbash, Edward R. Kastenhuber, Hisashi Kato, Melissa L. Bondy, John R. Ohlfest, and Hideho Okada

3420 **Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects**
Wei Zhang, Xiao-Dong Zhu, Hui-Chuan Sun, Yu-Quan Xiong, Peng-Yuan Zhuang, Hua-Xiang Xu, Ling-Qun Kong, Lu Wang, Wei-Zhong Wu, and Zhao-You Tang

3431 **Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies**
Nienke A. de Vries, Sophia W. Bruggeman, Danielle Hulsman, Hilda I. de Vries, John Zevenhoven, Tessa Buckle, Bob C. Hamans, William P. Leenders, Jos H. Beijnen, Maarten van Lohuizen, Anton J.M. Berns, and Olaf van Tellingen

IMAGING, DIAGNOSIS, PROGNOSIS

3442 **Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer**
Donal P. McLornan, Helen L. Barrett, Robert Cummins, Ultan McDermott, Cliona McDowell, Susie J. Conlon, Victoria M. Coyle, Sandra Van Schaeybroeck, Richard Wilson, Elaine W. Kay, Daniel B. Longley, and Patrick G. Johnston

3452 **Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non-Small Cell Lung Cancer**
Erin C. Farlow, Kalpa Patel, Sanjib Basu, Bao-Shiang Lee, Anthony W. Kim, John S. Coon, L. Penfield Faber, Philip Bonomi, Michael J. Liptay, and Jeffrey A. Borgia

3463 **Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR**
Kimberly Laskie Ostrow, Mohammad O. Hoque, Myriam Loyo, Marianna Brait, Alissa Greenberg, Jill M. Siegfried, Jennifer R. Grandis, Autumn Gaither Davis, William L. Bigbee, William Rom, and David Sidransky

3473 **Diverse Associations between ESRI Polymorphism and Breast Cancer Development and Progression**
Shian-ling Ding, Jyh-Cherng Yu, Shou-Tung Chen, Giu-Cheng Hsu, Huan-Ming Hsu, Jar Yi Ho, Yu Hsin Lin, Chien-Ching Chang, Cathy S.J. Fann, Chun-Wen Cheng, Pei-Ei Wu, and Chen-Yang Shen

CANCER THERAPY: CLINICAL

3485 **Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells**
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek

3495 **Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer**
Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Bisias, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marighoula Varla-Leftherioti, Michael Papamichail, Anastasios Thanos, Eric von Hofe, and Constantin N. Baxevanis

3507 **A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2**
Joseph Paul Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock-Bryan, Laurie Sherman, Stewart McCallum, Elisabeth I. Heath, Scott A. Boerner, and Patricia M. LoRusso


LETTERS TO THE EDITOR

3517 | **DNA Ploidy Cytometry Testing for Cervical Cancer Screening in China – Letter**
David M. Garner, Martial D. Guillaud, and Calum E. MacAulay

3517 | **DNA Cytometry Testing for Cervical Cancer Screening – Response**
Hua Tong, Rong Shen, YanJing Kan, ZhuMing Wang, YiQuan Wang, FengShan Li, FuZhou Wang, Jie Yang, and XiRong Guo

ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into *LoxP*-conditional *p53* (or *pten*); *Ink4a/Arf*; *K-Ras^{v12}*; *LucR* mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.



Clinical Cancer Research

16 (13)

Clin Cancer Res 2010;16:3297-3519.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/13>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.